X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2533) 2533
Publication (345) 345
Book Review (54) 54
Book Chapter (6) 6
Conference Proceeding (3) 3
Data Set (1) 1
Dissertation (1) 1
Magazine Article (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1873) 1873
index medicus (1792) 1792
oncology (1266) 1266
hematology (1045) 1045
rituximab (969) 969
female (902) 902
male (901) 901
middle aged (855) 855
aged (801) 801
non-hodgkins-lymphoma (724) 724
antineoplastic combined chemotherapy protocols - therapeutic use (694) 694
adult (678) 678
chemotherapy plus rituximab (638) 638
treatment outcome (637) 637
chemotherapy (594) 594
lymphomas (542) 542
plus rituximab (542) 542
elderly-patients (518) 518
cancer (514) 514
prognosis (504) 504
b-cell lymphoma (452) 452
aged, 80 and over (441) 441
care and treatment (412) 412
lymphoma, large b-cell, diffuse - drug therapy (411) 411
therapy (352) 352
survival (337) 337
lymphoma (331) 331
randomized controlled-trial (328) 328
antineoplastic agents - therapeutic use (324) 324
disease-free survival (279) 279
chop (276) 276
chronic lymphocytic-leukemia (272) 272
follicular lymphoma (272) 272
young adult (270) 270
antibodies, monoclonal - therapeutic use (269) 269
cyclophosphamide - administration & dosage (266) 266
trial (263) 263
cyclophosphamide (262) 262
rituximab plus cyclophosphamide (262) 262
retrospective studies (259) 259
diffuse large b-cell lymphoma (258) 258
open-label (257) 257
lymphoma, large b-cell, diffuse - pathology (255) 255
antineoplastic combined chemotherapy protocols - administration & dosage (254) 254
antibodies, monoclonal, murine-derived (231) 231
hemic and lymphatic diseases (229) 229
adolescent (222) 222
leukemia, lymphocytic, chronic, b-cell - drug therapy (222) 222
research (222) 222
lymphoma, large b-cell, diffuse - mortality (216) 216
antineoplastic combined chemotherapy protocols - adverse effects (215) 215
transplantation (211) 211
drug therapy (208) 208
non-hodgkin-lymphoma (208) 208
vincristine - administration & dosage (208) 208
analysis (206) 206
doxorubicin - administration & dosage (206) 206
1st-line treatment (205) 205
neoplasm staging (200) 200
antibodies, monoclonal, murine-derived - therapeutic use (199) 199
r-chop (198) 198
antibodies, monoclonal, murine-derived - administration & dosage (197) 197
phase-ii (197) 197
progression-free survival (193) 193
vincristine (193) 193
fludarabine plus cyclophosphamide (192) 192
phase-ii trial (191) 191
pharmacology & pharmacy (186) 186
prednisone - administration & dosage (186) 186
doxorubicin (184) 184
immunotherapy (183) 183
medicine & public health (181) 181
risk factors (180) 180
abridged index medicus (177) 177
cyclophosphamide - therapeutic use (177) 177
survival analysis (176) 176
patients (173) 173
chronic lymphocytic leukemia (172) 172
health aspects (171) 171
non-hodgkin's lymphomas (164) 164
immune system diseases (161) 161
doxorubicin - therapeutic use (160) 160
vincristine - therapeutic use (158) 158
hematology, oncology and palliative medicine (157) 157
lymphoma, non-hodgkin - drug therapy (157) 157
clinical trials (155) 155
medicine, general & internal (153) 153
prednisone - therapeutic use (153) 153
survival rate (152) 152
leukemia (151) 151
double-blind (147) 147
recurrence (147) 147
antibodies, monoclonal - administration & dosage (145) 145
bendamustine (144) 144
chop chemotherapy (144) 144
non-hodgkin lymphoma (144) 144
multicenter (143) 143
animals (142) 142
anti-cd20 monoclonal-antibody (140) 140
clinical trials as topic (139) 139
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2469) 2469
German (24) 24
French (18) 18
Russian (9) 9
Spanish (8) 8
Hungarian (3) 3
Polish (2) 2
Japanese (1) 1
Serbian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Haematology, ISSN 0007-1048, 12/2015, Volume 171, Issue 5, pp. 763 - 775
Summary Obinutuzumab is a novel glycoengineered Type‐II CD20 monoclonal antibody. CD20 is expressed in approximately 100% of children and adolescents with... 
rituximab‐sensitive BL | rituximab‐resistant BL | pre‐B‐ALL | obinutuzumab | rituximab | Rituximab | Obinutuzumab | Pre-B-ALL | Rituximab-sensitive BL | Rituximab-resistant BL | pre-B-ALL | NATURAL-KILLER-CELLS | ONCOLOGY GROUP-REPORT | rituximab-sensitive BL | rituximab-resistant ill | PHASE I/II | CHEMOTHERAPY PLUS RITUXIMAB | CHILDREN | IN-VITRO | ANTI-CD20 MONOCLONAL-ANTIBODY | NON-HODGKIN-LYMPHOMA | CHRONIC LYMPHOCYTIC-LEUKEMIA | RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA | HEMATOLOGY | Neoplasm Transplantation | Apoptosis - drug effects | Humans | Transplantation, Heterologous | Rituximab - pharmacology | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Animals | Caspases - metabolism | Antibodies, Monoclonal, Humanized - pharmacology | Survival Analysis | Cell Line, Tumor | Caspases - drug effects | Lysosomal-Associated Membrane Protein 1 - metabolism | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Killer Cells, Natural - drug effects | Mice | Interferon-gamma - biosynthesis | Molecular Targeted Therapy - methods | Burkitt Lymphoma - drug therapy | Disease Models, Animal | Drug Resistance, Neoplasm - drug effects | Antimitotic agents | Evaluation | Cell death | Patient outcomes | Monoclonal antibodies | Biochemistry | Comparative analysis | Antineoplastic agents | Burkitt's lymphoma
Journal Article
Journal Article
Annals of Hematology, ISSN 0939-5555, 8/2018, Volume 97, Issue 8, pp. 1417 - 1425
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 12, pp. 1250 - 1259
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2012, Volume 30, Issue 36, pp. 4462 - 4469
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2018, Volume 378, Issue 12, pp. 1107 - 1120
In a trial involving patients with relapsed or refractory chronic lymphocytic leukemia, the BCL2 inhibitor venetoclax in combination with rituximab resulted in... 
SURVIVAL | TRIAL | MEDICINE, GENERAL & INTERNAL | INDEPENDENT PREDICTOR | 17P DELETION | TARGETING BCL2 | PLUS RITUXIMAB | TP53 MUTATION | PROGRESSION-FREE | OPEN-LABEL | MINIMAL RESIDUAL DISEASE | Recurrence | Bendamustine Hydrochloride - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Neoplasm, Residual | Young Adult | Bendamustine Hydrochloride - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Aged, 80 and over | Adult | Female | Neutropenia - chemically induced | Rituximab - adverse effects | Kaplan-Meier Estimate | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sulfonamides - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Treatment outcome | Chronic lymphocytic leukemia | Diagnosis | Analysis | Chronic lymphatic leukemia | Cell survival | Hematology | Leukemia | Rituximab | Clinical trials | Oncology | Chromosome deletion | Lymphatic leukemia | Patients | Cancer therapies | Chemotherapy | Clonal deletion | Lysis | Response rates | Bone marrow | Chromosomes | Drug dosages | Chromosome 17 | Neutropenia | Life Sciences | Cancer
Journal Article
by Robak, Tadeusz and Jin, Jie and Pylypenko, Halyna and Verhoef, Gregor and Siritanaratkul, Noppadol and Drach, Johannes and Raderer, Markus and Mayer, Jiri and Pereira, Juliana and Tumyan, Gayane and Okamoto, Rumiko and Nakahara, Susumu and Hu, Peter and Appiani, Carlos and Nemat, Sepideh and Cavalli, Franco and Van Hoof, Achiel and Sheliga, Adriana and Teixeira, Adriana and Tomita, Akihiro and Rocafiguera, Albert Oriol and Suvorov, Alexander and Kuzmin, Alexy and Khojasteh, Ali and Mezlini, Amel and Golenkov, Anatoly and Bosly, Andre and Belch, Andrew and Van De Velde, Ann and Illes, Árpád and Mukhopadhyay, Ashis and Meddeb, Balkis and De Prijck, Bernard and Garichochea, Bernardo and Undar, Bulent and Gabarrón, Caballero and Cao, Carmen and Souza, Carmino and Farber, Charles and Won Suh, Cheol and Burcoveanu, Cristina Ileana and Cebotaru, Cristina Ligia and Truica, Cristina-Ligia and Maruyama, Dai and Belada, David and Ben Yehuda, Dina and Udovitsa, Dmitry and Dolores and Morra, Enrica and Späth-Schwalbe, Ernst and Gonzalez-Barca, Eva and Osmanov, Evgenii and Capote, Francisco Javier and Offner, Fritz and Cardenas, Galvez and Heß, Georg and Manikhas, Georgii and Babu, Govind and Rekhtman, Grigoriy and Rossi, Guiseppe and Marques, Herlander and Marques, Margarida and Bumbea, Horia and Wang, Zhao and Wang, Huaqing and Huang, Huiqiang and Choi, Ilseung and Bulavina, Irina and Lysenko, Irina and Avivi, Irit and Kryachok, Iryna and Zaucha, Jan Maciej and Novak, Jan and Díaz, Joaquín and Demeter, Judit and Alexeeva, Julia and Zhu, Jun and Vilchevskaya, Kateryna and Ishizawa, Kenichi and Mauricio, Kenny and Tobinai, Kensei and Ando, Kiyoshi and Abdulkadryrov, Kudrat and Shih, Lee-Yung and Kuzina, Lyudmila and Gumus, Mahmut and De Wit, Maike and Capra, Marcelo and Golubeva, Marina and Ojeda-Uribe, Mario and Kyselyova, Maryna and Taniwaki, Masafumi and Federico, Massimo and Crump, Michael and Baccarani, Michele and Ogura, Michinori and Egyed, Miklós and Udvardy, Miklos and Kurosawa, Mitsutoshi and Uike, Naokuni and ... and LYM-3002 investigators
The Lancet Oncology, ISSN 1470-2045, 11/2018, Volume 19, Issue 11, pp. 1449 - 1458
Journal Article